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Abstract
Introduction: Erythropoietin (EPO) enhances the circulating level of endothelial progenitor cells (EPCs), which has
been reported to be associated with prognostic outcome in ischemic stroke (IS) patients. The aim of this study was
to evaluate the time course of circulating EPC level and the impact of EPO therapy on EPC level and clinical
outcome in patients after acute IS.
Methods: In total, 167 patients were prospectively randomized to receive either EPO therapy (group 1) (5,000 IU
each time, subcutaneously) at 48 h and 72 h after acute IS, or serve as placebo (group 2). The circulating level of
EPCs (double-stained markers: CD31/CD34 (E1), CD62E/CD34 (E2) and KDR/CD34 (E3)) was determined using flow
cytometry at 48 h and on days 7 and 21 after IS. EPC level was also evaluated once in 60 healthy volunteers.
Results: Circulating EPC (E1 to E3) level at 48 h after IS was remarkably higher in patients than in control subjects
(P < 0.02). At 48 h and on Day 7 after IS, EPC (E1 to E3) level did not differ between groups 1 and 2 (all P > 0.1).
However, by Day 21, EPC (E1 to E3) level was significantly higher in group 1 than in group 2 (all P < 0.03).
Additionally, 90-day recurrent stroke rate was notably lower in group 1 compared with group 2 (P = 0.022).
Multivariate analysis demonstrated that EPO therapy (95% confidence interval (CI), 0.153 to 0.730; P = 0.006) and
EPC (E3) (95% CI, 0.341 to 0.997; P = 0.049) levels were significantly and independently predictive of a reduced 90-
day major adverse neurological event (MANE) (defined as recurrent stroke, National Institutes of Health Stroke scale
≥8, or death).
Conclusions: EPO therapy significantly improved circulating EPC level and 90-day MANE.
Trial registration number: ISRCTN: ISRCTN96340690
Introduction
Stroke, a growing epidemic, remains a leading cause of
mortality and disability worldwide [1-3]. Surprisingly,
while the epidemiology, etiologies, mechanisms, classifi-
cation, and prognostic outcomes of ischemic stroke (IS)
have been widely investigated for several decades, a safe
and effective treatment strategy for patients after acute
IS has not been fully developed [4-8].
Recently, thrombolysis using tissue plasminogen acti-
vator (tPA), a more aggressive management strategy, has
been shown to be effective for some acute IS patients
early after the onset of symptoms [9,10]. However, tPA
use is hampered by many limitations in daily clinical
practice [10-13]. In addition to its narrow indication for
only a small number of patients, tPA therapy has been
reported to have a relatively high incidence of intracra-
nial bleeding complications [13,14]. The majority of
acute IS patients, therefore, are still left without any spe-
cific treatment. Hence, finding a safe and effective thera-
peutic regimen for patients following acute IS, especially
those unsuitable for thrombolytic therapy, is of utmost
importance for physicians.
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anemic patients of various etiologies, especially for
patients with uremia. Interestingly, in addition to its role
in normalizing erythropoiesis, EPO has been clearly
shown to exert a myocardial protective effect against
ischemia-related damage [15-17]. In contrast, the neuro-
protective effect of EPO after acute IS is not well-
documented and the results are inconsistent [18-20].
The mechanisms underlying the anti-ischemic action of
EPO have been proposed to involve anti-apoptotic pro-
cesses [15,16], neovascularization, mobilization of
endothelial progenitor cells (EPCs), and angiogenesis
[21-23]. An increase in circulating levels of EPCs in
patients after acute IS has been demonstrated to be
strongly associated with favorable clinical outcomes in
our recent study [24]. Accordingly, we proposed that
other than its role in protecting myocardium against
ischemic insult, EPO therapy may enhance the circulat-
ing EPC level and improve neurological function and
clinical outcome in patients after acute IS.
Materials and methods
Study design
This clinical trial was approved by the Institutional
Review Committee on Human Research in Chang Gung
Memorial Hospital (No 96-1381A) in 2007 and con-
ducted at Kaohsiung Chang Gung Memorial Hospital.
This was a prospective, randomized, and placebo-con-
trolled trial. The primary objective was to evaluate the
safety and efficacy of two consecutive doses of EPO
(Epoetin beta, Roche, Basel, Switzerland) (5,000 IU each
time, subcutaneously) administered at 48 h and 72 h
after acute IS in improving the 90-day combined end-
point of recurrent stroke or death. The secondary objec-
tive of this study was to establish the time course of
circulating levels of EPCs in patients after acute IS and
the ability of two doses of EPO in enhancing circulating
EPC level. In addition, this study’s intent was to assess
the impact of EPO therapy on improving the combined
adverse neurological event (MANE) (defined as recur-
rent stroke, National Institutes of Health Stroke Scale
(NIHSS) ≥8, or death). The definition of the MANE was
based on our recent reports [8,24]. Instead of EPO, the
placebo-control subjects received a 1 mL normal saline
subcutaneous injection at 48 h and 72 h after acute IS.
Additionally, a neurologist blinded to the treatment allo-
cation assessed the outcomes. The medication (trial
agent) was given by a clinician blinded to the patients’
clinical condition. Patients who had a history of allergy
to EPO, hematological disorders including myeloproli-
ferative disorder, leukemia, thrombocythemia, polycythe-
mia, past history of deep vein thrombosis, abnormal
elevation of hemoglobin (male >14.5 gm/dL; female
>13.5 gm/dL) were excluded from this trial.
Calculation of sample size for specific objective
The study included consecutively admitted acute IS
patients at a single facility between October 2008 and
March 2010. For the primary objective of the study, an
e s t i m a t e ds a m p l es i z eo f1 0 6s t u d yp a t i e n t si ne a c h
group was based on the effective size with an a = 0.05,
a power of 80%, an anticipation of a combined end
point of 14.0% in placebo control vs. 4.0% with EPO
therapy. For the secondary objective of this study, an
estimated sample size of 93 study patients in each group
was based on the effective size with an a = 0.05, a
power of 80%, an average difference in circulating level
of EPCs between the EPO therapy and placebo-control
group of 0.32%, and a standard deviation of circulating
level of EPCs in EPO therapy was 0.7%. A 20% rate of
protocol violations and incomplete follow-up was
assumed. The calculation of sample size for specific
objective was based on our recent report [24].
Definition and exclusion criteria
Stroke was defined as sudden onset of loss of global or
focal cerebral function persisting for more than 24 h.
Patients of any age with acute IS were eligible. Inclusion
criteria included a scoring of >2 on the NIHSS (scores
up to 8 indicate moderate neurological status disability)
and a time window of ≤48 h from onset of symptoms to
blood sampling (at 48 h after IS) and study drug admin-
istration (time to treatment just after blood sampling).
Patients with a history of the following were excluded
from the study: intracranial hemorrhage, surgery or
trauma within the preceding three months, abnormal
liver function, hematology disorders, renal insufficiency
(serum creatinine >1.5 mg/dL), malignancy, febrile dis-
orders, acute or chronic inflammatory disease at study
entry, liver cirrhosis, atrial fibrillation, congestive heart
failure, contraindications for Magnetic Resonance Ima-
ging (MRI) examination, no evidence of acute IS by
MRI study, myeloproliferative disorder, antibodies or
allergies to EPO, pregnancy, tPA therapy for acute IS, or
a hemoglobin level >15.0 gm/dL.
An overview of the study protocol of this clinical trial
is shown in Figure 1. From October 2008 through
March 2010, consecutive patients with acute IS were
enrolled by the responsible neurologists at the institute.
Patients were randomly assigned to different treatment
groups after giving informed consent. Over a period of
18 months, 230 consecutive patients with IS occurring
less than 48 h prior to blood sampling were recruited.
Twenty-five (23.1%) of the 108 EPO-treated (group 1)
patients were excluded due to unavailable MRI data
(two patients), paroxysmal atrial fibrillation (four
patients), refused EPO therapy (fifteen patients), or
incomplete follow-up (four patients) that occurred later
after the IS. Therefore, the remaining 83 patients
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(17.9%) of the 112 patients in the placebo control group
(group 2) were excluded due to unavailable MRI data
(four patients), paroxysmal atrial fibrillation (two
patients), fever and sepsis (two patients), fever of
unknown etiology (six patients), or incomplete follow-
up (six patients) that occurred later after the IS. Addi-
tionally, eight patients (7.1%) who insisted on knowing
the type of therapeutic drug after enrollment were also
excluded even though their blood samples were
Figure 1 Schematic overview of the trial protocol. EPO, erythropoietin; MRI, magnetic resonance imaging; PAF, paroxysmal atrial fibrillation.
Yip et al. Critical Care 2011, 15:R40
http://ccforum.com/content/15/1/R40
Page 3 of 11collected. Therefore, the remaining 84 patients consti-
tuted group 2 (placebo control) of this study.
Sixty age- and gender-matched healthy volunteers
were also studied for circulating level of EPCs. Informed
consent was obtained from all study subjects.
Neurological assessment
Evaluation of the physical function and degree of neuro-
logical impairment in the stroke patients was based on
the National Institutes of Health Stroke Scale (NIHSS)
[25] during the acute (at 48 h), convalescent (on Day
21), and chronic (Day 90) phases of stroke by neurolo-
gists blinded to the treatment allocation (double-blind
study). Moderate neurological impairment (that is, neu-
rological sequelae that requires partial support in daily
activities) was defined as a score of ≥8 on NIHSS, a
modified criteria reported previously [4]. In addition to
NIHSS, assessments only during admission included
functional measures, Barthel Index [26] [range from 100
(no deficit) to 0 (complete dependence or death)], and
modified Rankin Scale score [27] (range from 0 (no resi-
dual symptoms) to 6 (indicating death)).
Imaging studies and laboratory investigations
In addition to full clinical assessment, other examina-
tions performed also included chest X-ray film, routine
brain computed tomography, duplex scanning of the
carotid arteries, and routine cardiac analysis by 12-lead
electrocardiogram and echocardiography. Moreover,
white blood cell (WBC) count, red blood cell (RBC)
count, hemoglobin, and biochemical data were acquired
at 48 h and on days 7 and 21 after acute IS.
The radiological diagnosis of acute IS included brain
computed tomography showing a new finding of low
attenuation density in focal or diffuse brain area; or
MRI examination showing area(s) of high intensity
(bright spots) on diffusion weighted image (DWI) MRI
or lower intensity on apparent diffusion coefficient
(ADC) value MRI.
Blood sampling and assessment of circulating EPC level
by flow cytometry
Blood samples were obtained at 48 h (acute phase) and
on days 7 (recovery phase) and 21 (convalescent phase)
after IS at 9.00 a.m. for assessment of the serial changes
in circulating level of EPCs in IS patients. Blood samples
were also obtained in control subjects who participated
in a health screening program in our Health Clinic once
at 9.00 a.m.
Ten milliliters of blood was drawn from the antecubi-
tal vein into a vacutainer containing 3.8% buffered
sodium heparin. Mononuclear cells (MNCs) were then
isolated by density-gradient centrifugation of Ficoll 400
(Ficoll-Plaque™ plus, Amersham Biosciences, Uppsala,
Sweden), based on our recent report [24]. The MNCs
were washed twice with phosphate buffered saline (PBS)
and centrifuged before incubation with 1 mL blocking
buffer for 30 minutes at 4°C. Cell variability of >95.0%
was noted in each group.
A flow cytometric method for identification of EPCs
derived from peripheral blood has been reported in our
recent studies and also those by others [24,28,29].
Briefly, the isolated MNCs (4 × 10
5) were incubated for
30 minutes at 4°C in a dark room with monoclonal anti-
bodies against kinase insert domain-conjugating receptor
(KDR) (Sigma, St. Louis, MO, USA), the fluorescein iso-
thiocyanate (FITC)-conjugated CD34 and the phycoery-
thrin (PE)-conjugated CD31, and CD62E (Becton
Dickinson, San Jose, CA, USA) to determine the EPC
surface markers of CD31/CD34 (E1), CD62E/CD34 (E2),
and KDR/CD34 (E3), The control ligand (IgG-PE conju-
gate) was used to detect any nonspecific association and
define a threshold for glycoprotein binding. For analysis
of KDR, the MNCs were further incubated with PE-
conjugated anti-mouse antibody made in goat. After
staining, the MNCs were fixed in 1% of paraformalde-
hyde. Quantitative two-colored flow cytometric analysis
was performed using a fluorescence-activated cell sorter
(FACSCalibur™ system; Beckmen Coulter, Brea, CA,
USA). Each analysis included 30,000 cells per sample.
The assays for EPCs (E1t o3 ) in each sample were per-
formed in duplicate, with the mean level reported.
Intra-assay variability based on repeated measurement
of the same blood sample was low with a mean coeffi-
cient of variance being 3.9% and 3.6% in stroke patients
and in normal subjects, respectively.
Medications
Aspirin was the first choice for acute stroke patients
unless they were allergic or intolerant to aspirin, includ-
ing a history of peptic ulcer or upper gastro-intestinal
tract bleeding during aspirin therapy. Clopidogrel was
used in patients intolerant to aspirin therapy. Other
commonly used drugs included statins, angiotensin con-
verting enzyme inhibitors (ACEIs)/angiotensin II type I
receptor blockers (ARB), diuretics, calcium channel
blocking agents, and beta blockers.
Statistical analysis
Chi-square test or Fischer’se x a c tt e s tw a su s e dw h e r e
appropriate. Comparisons of means were performed
using Student t-test. Continuous variables at three time
points in the three groups were compared using
repeated measure of ANOVA followed by Tukey multi-
ple comparison procedure. Multivariate logistic regres-
sion analysis was utilized for identifying the independent
predictors of EPCs level and prognostic outcomes. Sta-
tistical analysis was performed using SAS statistical
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NC, USA). A value of P < 0.05 was considered statisti-
cally significant.
Results
Baseline characteristics and laboratory findings of study
patients and healthy controls
Table 1 displays the baseline demographic and labora-
tory findings of both IS patients (that is, group 1 =
EPO-treated group, group 2 = placebo control) and
healthy controls. There were no significant differences
in terms of age, gender, body mass index, diastolic
blood pressure (DBP), total cholesterol level, low-density
lipoprotein (LDL), serum creatinine level, RBC count,
hemoglobin, or hematocrit level between three groups.
However, high-density lipoprotein (HDL) was notably
lower in IS patients than in healthy controls. In contrast,
WBC count and systolic blood pressure (SBP) were
remarkably higher in groups 1 and 2 of IS patients com-
pared with the control subjects. Moreover, the level of
circulating EPCs (E1t o3 ) was substantially higher in
both groups of IS patients than in healthy controls.
The risk factors of cerebrovascular disease, incidence
of previous stroke documented by history or MRI, old
myocardial infarction, or hemoglobin A1C (HbA1C)d i d
not differ between group 1 and group 2 patients.
Table 1 Comparison of baseline characteristics and laboratory findings among three groups
Variables Group 1 (n = 83)† Group 2 (n = 84)† Healthy Control (n = 60) P-value*
Age (y) (mean ± SD), 63.7 ± 11.4 67.0 ± 11.1 64.1 ± 6.0 0.078
Male, % (n) 65.1% (54) 66.7% (56) 65.0% (39) 0.969
Hypertension, % (n) 63.9% (53) 73.8% (62) – 0.165
Diabetes mellitus, % (n) 37.4% (31) 32.1% (27) – 0.480
Current smoking, % (n) 36.1% (30) 273.4% (23) – 0.224
Previous stroke by history, % (n) 24.1% (20) 21.4% (18) – 0.681
Previous stroke by MRI, % (n) 62.7% (52) 57.1% (48) – 0.468
Old myocardial infarction, % (n) 8.4% (7) 6.0% (5) – 0.549
RBC count (×10
6/μL) 4.74 ± 0.67 4.68 ± 0.68 4.81 ± 0.64 0.561
Hemoglobin (g/dL) 14.0 ± 2.0 14.1 ± 1.8 14.05 ± 1.56 0.963
Hematocrit (%) 41.3 ± 5.9 41.4 ± 6.0 40.9 ± 6.1 0.877
WBC count (×10
3/μL) 7.82 ± 2.38
a 7.83 ± 2.37
a 5.91 ± 1.84
b <0.0001
Circulating level of EPCs at 48 h
CD31/CD34 (%) 1.65 ± 0.91
a 1.75 ± 1.03
a 1.13 ± 0.74
b 0.0003
CD62E/CD34 (%) 1.21 ± 0.86
a 1.16 ± 0.76
a 0.93 ± 0.83
b 0.025
KDR/CD34 (%) 1.34 ± 0.77
a 1.37 ± 0.89
a 1.03 ± 0.79
b 0.03
Total cholesterol level (mg/dL) 186.6 ± 41.2 190.1 ± 42.7 193.2 ± 36.4 0.621
HDL (mg/dL) 44.6 ± 10.8
a 49.2 ± 17.3
a 53.8 ± 14.8
b 0.001
LDL (mg/dL) 116.2 ± 35.7 115.2 ± 39.4 117.2 ± 30.9 0.949
Creatinine (mg/dL) 1.00 ± 0.38 1.02 ± 0.43 1.01 ± 0.24 0.915
BMI (kg/m
2) 25.1 ± 3.5 24.2 ± 3.9 24.7 ± 3.1 0.225
HbA1C level, % 6.73 ± 1.85 6.96 ± 1.88 – 0.468
SBP (mm Hg) 144 ± 20
a 143 ± 21
a 136 ± 18
b 0.031
DBP (mm Hg) 83 ± 12 84 ± 11 85 ± 11 0.231
Significant ECCA stenosis, % (n) 24.1% (20) 17.9%% (15) – 0.322
Statin therapy 43.4% (36) 45.2% (38) – 0.808
ACEI/ARB therapy 39.8% (33) 38.1% (32) – 0.826
EPO therapy-related adverse events
Allergy 0% (0) 0% (0) –
Polycythemia 0% (0) 0% (0) –
Thrombosis event 0% (0) 0% (0) –
*: by Chi-square test or Fisher’s exact test for categorical data; by t-test or one-way ANOVA for continuous data.
Letters (
a, b) indicate significant difference (at 0.05 level) by Tukey multiple comparison procedure.
†: group 1, with EPO treatment; group 2, without EPO treatment.
Data are expressed as mean ± SD or % (No.) of patients.
ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin II type I receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; ECCA, extra-cranial
carotid artery; EPC, endothelial progenitor cell; EPO, erythropoietin; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MRI,
magnetic resonance imaging; SBP, systolic blood pressure; RBC, red blood cell; WBC, white blood cell.
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carotid artery (ECCA) stenosis (defined as ≥50% stenosis
by carotid Doppler measurement) and the status of both
statin and ACEI/ARB treatment did not significantly dif-
fer between the two groups. Importantly, no side effect
of EPO therapy was recorded. This finding indicates
that EPO therapy with the regimen of two consecutive
dosages of 5,000 IU per patients is likely to be safe.
Laboratory findings, circulating level of EPCs at three
time points, neurological status, and clinical outcome
after acute IS
Table 2 shows that there was al s on os i g n i f i c a n td i f f e r -
ence between the circulating levels of EPCs (E1 to E3)a t
48 h and on Day 7 between both groups of patients.
Moreover, the RBC and WBC counts, hemoglobin, and
hematocrit on Day 21 were similar among these
patients. However, by Day 21, the circulating level of
EPCs (E1 to E3) was substantially higher in group 1 than
in group 2.
The scores of NIHSS, Barthel Index, and modified
Ranking Scale score upon presentation (at 48 h after
acute IS) did not differ between group 1 and group 2
(Table 3). Additionally, the mean NIHSS score on Day
90 did not differ between group 1 and group 2. How-
ever, the incidence of a NIHSS score ≥8o nD a y9 0
was notably lower in group 1 than in group 2. Further-
more, although the 90-day mortality was similar
between the two groups, the incidence of recurrent
stroke during a 90-day follow-up was notably lower in
group 1 than in group 2. Besides, the incidence of
90-day major adverse neurological event (that is,
MANE) was significantly reduced in group 1 compared
with group 2.
Correlation between three individualized neurological
assessment scales upon presentation and the circulating
level of EPCs
The Spearman rank correlation analysis did not identify
significant correlation of circulating level of EPCs (E2)
to either modified Ranking Scale score or to Barthel
Index at 48 h after acute IS (Figure 2). On the other
hand, a significant negative correlation was noted
between the circulating level of EPCs (E1 and E3)a n d
both modified Ranking Scale and Barthel Index at 48 h
after acute IS. Besides, a significant negative correlation
also was noted between the circulating level of EPCs (E1
to E3) and NIHSS at 48 h after acute IS.
Time course of circulating level of EPCs
The circulating level of EPCs (E1 to E3)d i dn o ts i g n i f i -
cantly alter at the chosen time points (48 h, on days 7
and 21) after acute IS in group 2 patients (Table 4).
Consistently, the circulating level of EPCs did not signif-
icantly change between at 48 h and on Day 7 after acute
IS in group 1 patients. However, the circulating level of
EPC (E1 to E3) was substantially increased on Day 21
compared with that at 48 h and on Day 7 after acute IS
in group 1. These findings indicate that the effect of
EPO therapy on boosting circulating EPC level was gra-
dually increased after one week and up to a significantly
higher level on Day 21 after acute IS.
Table 2 Laboratory findings and circulating level of EPCs between IS patients with and without EPO treatment
Variables Group 1† (n = 83) Group 2† (n = 84) P-value*
Circulating level of EPCs at 48 h
CD31/CD34 (%) 1.65 ± 0.91 1.75 ± 1.03 0.530
CD62E/CD34 (%) 1.21 ± 0.86 1.16 ± 0.76 0.704
KDR/CD34 (%) 1.34 ± 0.76 1.37 ± 0.89 0.791
Circulating level of EPCs on day 7
CD31/CD34 (%) 1.52 ± 1.06 1.48 ± 0.89 0.801
CD62E/CD34 (%) 1.11 ± 0.76 1.14 ± 0.75 0.855
KDR/CD34 (%) 1.16 ± 0.70 1.24 ± 0.80 0.523
Circulating level of EPCs on day 21
CD31/CD34 (%) 2.28 ± 1.48 1.64 ± 0.79 0.002
CD62E/CD34 (%) 1.50 ± 1.13 1.14 ± 0.72 0.030
KDR/CD34 (%) 1.81 ± 1.25 1.22 ± 0.71 0.001
RBC count (×10
6/mL) on day 21 4.56 ± 0.73 4.62 ± 1.16 0.719
Hemoglobin (g/dL) on day 21 13.7 ± 1.9 13.8 ± 3.3 0.746
Hematocrit (%) on day 21 41.0 ± 5.4 39.9 ± 6.4 0.309
WBC count (×10
3/mL) on day 21 7.68 ± 6.30 7.27 ± 2.47 0.645
*: by t-test.
†: group 1 = with EPO treatment; group 2 = without EPO treatment.
EPC = endothelial progenitor cell; EPO = erythropoietin; RBC = red blood cell; WBC = white blood cell.
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90-day MANE
Univariate analysis of enrollment variables in Tables 1
and 3 demonstrated that serum levels of total cholesterol
and LDL were significantly associated with 90-day
MANE (Table 5). On the other hand, EPO therapy,
increase in circulating level of EPC (E3)a t4 8ha f t e rI S ,
SBP and DBP were favorable factors strongly predictive
of freedom from 90-day MANE. Interestingly, further
analysis revealed that the incidence of MANE varied with
SBP upon presentation (subgroup (A) ≤135 mmHg, sub-
group (B) >135 mmHg to ≤150 mmHg and subgroup (C)
>150 mmHg) were 38.3% (n = 23/60), 17.0% (9/53), and
24.1% (13/54), respectively. As compared with the other
Table 3 Comparisons of neurological status and clinical outcome between IS patients with and without EPO treatment
Variables Group 1† (n = 83) Group 2† (n = 84) P-value*
NIHSS at 48 h 6.78 ± 4.60 7.35 ± 7.55 0.562
Modified Rankin Scale score at 48 h 3.23 ± 1.38 2.89 ± 1.62 0.152
Barthel Index at 48 h 55.7 ± 30.5 59.5 ± 36.0 0.467
NIHSS on day 90 4.27 ± 5.39 5.49 ± 7.77 0.239
Recurrent stroke, % (n) 0% (0) 9.5% (8) 0.007
90-day mortality, % (n) 2.4% (2) 1.2% (1) 0.621
Primary end point, % (n)‡ 2.4% (2) 10.7% (9) 0.057
NIHSS ≥ 8.0 14.5% (12) 29.8% (25) 0.017
Combined MANE, % (n)¶ 16.9% (14) 36.9% (31) 0.004
*: by Chi-square test or Fisher’s exact test for categorical data; by t-test for continuous data.
†: group 1 = with EPO treatment; group 2 = without EPO treatment.
‡: defined as 90-day combined recurrent stroke or death.
¶: MANE = major adverse neurological event (defined as NIHSS ≥8, recurrent stroke or death on Day 90 after acute IS).
IS, ischemic stroke; NIHSS, national institutes of health stroke scale.
Figure 2 Correlation between circulating level of endothelial progenitor cells (EPCs) and three individualized neurological assessment
scales. NIHSS, National Institutes of Health Stroke scale; MRSS, modified Ranking Scale score.
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with a reduction in 90-day MANE (all P < 0.05).
Multiple stepwise logistic regression analysis demon-
strated that total cholesterol level was significantly and
independently predictive of 90-day MANE (Table 5). In
contrast, SBP, EPO treatment, and circulating EPC (E3)
level were significantly and independently predictive of
improvement in 90-day MANE.
Univariate and multivariate analyses of predictors for 90-
day combined end point (recurrent stroke or death)
Univariate analysis of enrollment variables in Tables 1
and 3 demonstrated that serum levels of creatinine were
significantly correlated with 90-day combined end point
(Table 6). On the other hand, EPO therapy and serum
level of HDL were significantly predictive of freedom
from a 90-day combined end point. Multiple stepwise
logistic regression analysis demonstrated that EPO
treatment and serum level of HDL were significant and
independent predictors of freedom from 90-day com-
bined end point (Table 6).
Discussion
This study, which investigated the safety and efficacy of
EPO therapy in boosting the circulating level of EPCs
and improving 90-day clinical outcome in patients after
acute IS, provides some notable information. First, as
compared with the healthy controls, circulating levels of
EPCs were remarkably increased in patients after acute
IS. Our findings are comparable with those of our
recent report [24]. Second, there were no serial changes
in circulating EPC level after acute IS. Third, only EPO
therapy in the acute phase of IS was associated with an
increase in circulating levels of EPC at the convalescent
phase of IS. Besides, EPO therapy was significantly asso-
ciated with a reduction in the incidence of recurrent
stroke. Fourth in importance was the fact that, in addi-
tion to being without side effects, EPO therapy and
increased circulating EPC (E3, KDR/CD34) were signifi-
cantly and independently predictive of a decrease in
90-day MANE.
Value and level of circulating EPCs after acute IS
Abundant data have shown that EPCs in bone marrow
microenvironment [30] migrate to circulation in
response to ischemia-related organ dysfunction for
angiogenesis [24,31,32]. The present study that demon-
strated a marked increase in circulating EPC levels in
patients after acute IS compared with the normal con-
trols, therefore, reinforced the findings of the previous
reports [24,31,32].
Unexpectedly, the present study failed in demonstrat-
ing a significant fluctuation in the circulating level of
EPC in our patients at three phases after acute IS. Inter-
estingly, as compared with both Barthel Index and mod-
ified Ranking Scale score, NIHSS showed a notably
better correlation with the circulating level of EPCs (E1
to E3) at 48 h after IS. Of importance is the fact that the
circulating levels of EPCs were found to be inversely and
Table 4 Time course of circulating level of EPCs
Variables At 48 h On Day 7 On Day 21 P-
value*
Circulating EPCs in group 1
CD31/CD34 (%) 1.65 ± 0.91
a 1.52 ± 1.06
a 2.28 ± 1.48
b <0.0001
CD62E/CD34 (%) 1.21 ± 0.86
a 1.11 ± 0.76
a 1.50 ± 1.13
b 0.0409
KDR/CD34 (%) 1.34 ± 0.76
a 1.16 ± 0.70
a 1.81 ± 1.25
b 0.0001
Circulating EPCs in group 2
CD31/CD34 (%) 1.75 ± 1.03 1.48 ± 0.89 1.64 ± 0.79 0.071
CD62E/CD34 (%) 1.16 ± 0.76 1.14 ± 0.75 1.14 ± 0.72 0.973
KDR/CD34 (%) 1.37 ± 0.89 1.24 ± 0.80 1.22 ± 0.72 0.267
*: by repeated measure of ANOVA.
Letters (
a, b) indicate significant difference (at 0.05 level) by Tukey multiple
comparison procedure.
Table 5 Logistic regression analysis of predictors for
combined MANE on Day 90 after ischemic stroke
Variables Odds Ratio 95% CI P-value
Univariate
Systolic blood pressure* 0.978 0.960 to 0.996 0.017
Diastolic blood pressure* 0.962 0.931 to 0.994 0.019
Total cholesterol level 1.012 1.003 to 1.021 0.006
Low-density lipoprotein 1.013 1.003 to 1.022 0.010
EPO therapy 0.347 0.168 to 0.717 0.004
KDR/CD34 0.609 0.373 to 0.995 0.048
Multiple Stepwise
Total cholesterol level 1.012 1.003 to 1.021 0.010
Systolic blood pressure* 0.979 0.960 to 0.998 0.031
KDR/CD34 0.583 0.341 to 0.997 0.049
EPO therapy 0.334 0.153 to 0.730 0.006
CI, confidence interval; EPO, erythropoietin.
MANE, major adverse neurological event (defined as NIHSS ≥8, recurrent
stroke or death on day 90 after acute IS); NIHSS, national institutes of health
stroke scale.
* Indicates the continuity of systolic and diastolic blood pressure to be used
for statistical analysis but not the history of hypertension.
Table 6 Predictors for combined death and recurrent
stroke on Day 90 after ischemic stroke
Variables Odds Ratio 95% CI P-value
Univariate
High-density lipoprotein 0.921 0.857 to 0.990 0.026
EPO therapy 0.206 0.043 to 0.983 0.004
Creatinine 3.250 1.045 to 10.109 0.042
Multiple Stepwise
High-density lipoprotein 0.909 0.842 to 0.983 0.016
EPO therapy 0.155 0.031 to 0.772 0.023
CI, confidence interval; EPO, erythropoietin; MANE, major adverse neurological
event.
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neurological scores at 48 h after acute IS. Our recent
study [24] has revealed that a reduced circulating EPC
level was significantly related to severe neurological
impairment in patients after acute IS. Importantly, an
increase in circulating levels of EPCs was found to be
independently predictive of an improved 90-day MANE
after IS in the current study. Interestingly, previous stu-
dies have shown that bone marrow-derived circulating
EPCs play an essential role in repairing endothelial
injury and participating directly in angiogenesis and vas-
culogenesis in systemic vascular beds [33,34]. Besides,
contribution of EPCs in maintenance and repair of the
cerebral vasculature has also been revealed in ischemia-
related cerebrovascular dysfunction [35]. Therefore, our
results strengthen the findings of previous studies
[33-35]. Taken together, the results of the present study
not only corroborate that of our recent report [24], they
also encourage the possible use of the level circulating
EPCs as a biomarker for risk stratification in patients
after acute IS.
Impact of EPO therapy effectively improves 90-day
prognostic outcome after IS
Interestingly, while the neuroprotective mechanisms
underlying EPO therapy have been well investigated in
experimental studies [36] including the enhancement of
mobilization of EPCs to circulation, attenuation of
inflammatory response and cellular apoptosis, and
reduction in oxidative stress [24,37-40], only a few clini-
cal interventional studies [19,20,41] have been per-
formed to further clarify the validity of this therapeutic
option in improving the clinical outcome of patients
after acute IS. On top of that, the data of these clinical
observational studies [19,20,41] are too inconsistent to
reach a significant conclusion. In the current study, we
found an association between EPO therapy and reduc-
tion of the incidence of 90-day recurrent stroke. The
most important finding in the present study is that EPO
therapy was an independent predictor of improvement
in 90-day MANE and in 90-day combined end point.
Therefore, our findings, in addition to strengthening
those of previous studies [19,41], highlight the therapeu-
tic potential of EPO in patients after IS who are not sui-
table candidates for thrombolysis.
Contrary to the findings of our study, the results of
one recent clinical trial did not find an additional bene-
fit of EPO in improving clinical outcome of patients
with acute IS undergoing tPA therapy as compared with
placebo-controls [20]. However, subgroup analysis of the
study showed that EPO therapy improved 90-day clini-
cal outcome of the non-tPA patients. Thus, the findings
in subgroup analysis of the study [20] support the
results of our study. The reason accounting for the
partially consistent results between this recent clinical
study [20] and ours remain uncertain. However, there
are some issues worthy of being addressed regarding
that study [20]. First, as compared with the relative low
dose of EPO adopted in our study, a very high EPO
dosage used in that clinical trial [20] may raise other
unidentified confounding effects such as a polycythemia
and thrombosis event, thereby influencing patient out-
comes. Second, of distinctive particularity was the
majority of patients enrolled in that trial [20] were trea-
ted by tPA (a violation of their original protocol), which
introduced another variable in assessing the benefit of
EPO in improving patient outcome after IS, as tPA ther-
apy may induce bleeding complications that outweigh
the benefit of EPO treatment [13,14,20].
Other independent predictors of 90-day MANE
The impact of blood pressure on clinical outcome after
acute IS has been extensively investigated [42-44].
Excessive elevation, reduction, and variability in blood
pressure have been reported to be independent prognos-
tic predictors for poor clinical outcome after acute IS
[43,44]. In the current study, another important finding
is that SBP was an independent predictor of 90-day
MANE. Further analysis demonstrated that SBP ≥135
mm Hg and ≤150 mm Hg were significantly associated
with a favorable 90-day clinical outcome. Previous study
[41] has also shown that satisfactory control of SBP
within 140 to 150 mm Hg was the optimal therapy for
improving clinical outcome after acute IS. Therefore,
our findings corroborated those of previous studies
[42-44].
Another notable finding in the current study is that
total cholesterol level was also found to be an indepen-
dent factor for predicting 90-day MANE in the current
study. Conversely, HDL was strongly and independently
associated with freedom from 90-day combined end
point. Hypercholesterolemia and lower level of HDL-
cholesterol have been identified as important contribut-
ing factors to the development of atherosclerosis and
acute arterial obstructive syndrome [45,46]. Accordingly,
our finding re-emphasizes the importance of serum cho-
lesterol and HDL control in patients after acute IS.
Study limitations
This study has limitations. First, practically, it is impos-
sible to routinely perform intracranial angiographic
examination for the acute IS patients. Therefore, the
results of our study did not provide information to
address the correlation between the circulating level of
EPCs and angiogenesis, such as collateral formation in
the brain infarct area. Second, because rather restrictive
inclusion criteria were designed in the current study,
some critical patients were excluded at the initial
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Page 9 of 11enrollment period. Thus, the 90-day mortality rate was
relatively low in the current study. Therefore, the impact
of EPO therapy on 90-day mortality could not be
assessed. Finally, although a statistically significant rela-
tionship between EPO therapy and a reduction in the
incidence of 90-day recurrent stroke was noted in the
current investigation, this study did not give cutoff and
define positive and negative predictive values as well as
provide sensitivities and specificities of EPO on clinical
outcome because this study was not actually designed to
perform a prognostic study.
Conclusions
EPO therapy significantly increased circulating EPC
levels and was strongly associated with favorable 90-day
clinical outcomes after IS. The results of this study,
therefore, may encourage the application of EPO treat-
ment in patients unsuitable for thrombolytic therapy
after acute IS.
Key messages
￿ EPO therapy in acute phase of IS was associated
with an increase in circulating levels of EPCs at the
convalescent phase of IS.
￿ EPO therapy was significantly associated with a
reduction in the incidence of 90-day recurrent
stroke.
￿ EPO therapy and increased circulating EPC (E3)
levels were significantly and independently predictive
of decreased 90-day MANE.
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